RED OCEAN
✦ Deeply researched

Screen recorder for gmail extension

35
opportunity
Demand: 25
Competition gap: 65
Margin: 55
Ease of entry: 40
Market momentum: 50
Bottom line

The call

Screen recording for email is Loom's category. Vidyard, Wistia, Descript, and Google Vids Screen Recorder (Workspace-native free) own distribution. A pure Gmail recorder without a vertical workflow is RED OCEAN.

Demand

Is the demand real?

Async video for sales and support is established behavior. Loom's Chrome-extension growth path is the playbook everyone copies; alternatives lists are long in 2026.

Competitors and products found

What already exists in this space

Market trend

Growing or fading?

▬ Flat

Category is mature; growth is incremental, not greenfield.

Search demand

What people search

screen recorder for gmail extensionbest screen recorder for gmail extensionscreen recorder for gmail extension chrome
The opening

The wedge competitors are missing

Only Gmail-compose native workflow for one vertical (SDR sequences or support macros) with CRM tags — not another Loom.

Avoid. Category is closed for new generalists.

Competitor teardown

Who you are up against, and how to beat each one

Loom (Atlassian)
Positioning
Offer / pricing
How to beat them
Vidyard
Positioning
Offer / pricing
How to beat them
Google Vids Screen Recorder
Positioning
Offer / pricing
How to beat them
Screen Recorder Pro / AppSumo clones
Positioning
Offer / pricing
How to beat them
Ideal customer

Your perfect first customer

SDR teams and support agents who live in Gmail and hate tab-switching to Loom.

The real risks

What could kill it, and how to de-risk

Money to build itFunding you could apply for

Open grants matched to this idea's space. Confirm eligibility and deadlines on the official portal before applying.

Apply AI: Piloting AI-based image screening in medical centres
Digital Europe Programme (DIGITAL) · European Union · closes 10/01/2026
View on official portal →
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
National Institutes of Health · United States · closes 09/07/2026
View on official portal →
See all funding opportunities →